Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug PharmaphorumTakeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.HematologyRead full story pharminent August 31, 2026 (Last updated: September 1, 2026) Pharmaphorum Takeda and Protagonist’s hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera. Hematology Read full story Post navigation Previous: ESC 2026: Evolocumab explores new frontiers in CV disease preventionNext: Lilly adds to immune drug pipeline with $2.9B Merida buyout Related Stories Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026 Regulatory Jazz secures FDA approval for Ziihera in advanced HER2+ GEA pharminent August 26, 2026
